— Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI —

TOKYO, March 13, 2026 /PRNewswire/ — PRISM BioLab Co., Ltd. (“PRISM”) and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the “Collaboration”) to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins, and complex receptor systems.

The Collaboration unites PRISM’s PepMetics^® chemistry — conformationally rigid, three-dimensional small molecules engineered to mimic α-helix and β-turn motifs — with Receptor.AI’s physics-informed, multi-objective AI navigation engine. By integrating their technologies, the companies aim to generate innovative hit, lead and clinical candidate compounds against PPI and membrane-protein targets that have proven challenging for conventional small molecule drug discovery, with an initial focus on metabolic diseases, including obesity.

The Collaboration will initially focus on one selected receptor target for metabolic disease. Receptor.AI will carry out molecular design using the combination of PRISM’s chemical space and Receptor.AI’s design algorithms. In parallel, the companies will jointly engage pharmaceutical partners interested in utilizing the combined capabilities of both technologies.

The Collaboration aims not only to generate clinical candidates—typically the goal of joint research — but also to showcase the power of combined technologies and to acquire specialized know‑how, which will be the basis for proposals to potential partner companies, enabling the expansion of future collaborative opportunities.

“We are very pleased to partner with Receptor.AI on this exciting project,” said Dai Takehara, President & CEO of PRISM BioLab. “We have developed PepMetics^® Technology, a highly effective drug discovery platform targeting PPIs, and possess a unique peptide‑mimetic small‑molecule library, the PepMetics^® Library. We believe this library can be applied not only for intracellular PPI drug discovery but also for membrane proteins, which are not easily targeted by small molecules. With Receptor.AI’s AI‑based molecular design technologies ranging from peptides to small molecules, we expect the potential of the PepMetics^® Library to expand even further.”

“We’re excited to partner with PRISM BioLab to move intracellular and receptor-driven discovery from ‘screening harder’ to navigating smarter,” said Dr. Alan Nafiiev, Founder & CEO of Receptor.AI. “PRISM contributes a high-quality, structurally constrained virtual chemical space designed for practical progression. We’re bringing QuorumMap — our chemical space navigation engine — together with structure- and physics-informed modeling and multi-objective optimization to continuously reallocate compute and experimental focus toward the compounds most likely to translate: not just binders, but candidates that balance selectivity with the permeability and stability needed for oral exposure. The goal is a repeatable, decision-driven loop that turns difficult intracellular biology into actionable chemical hypotheses and ranked molecules ready for synthesis and testing.”

PRISM and Receptor.AI share a common philosophy of “pursuing new approaches to drug discovery”—creating innovative therapeutics more rapidly, rationally, and with scientific rigor. Through this Collaboration, the companies aim to create synergies by mutually adopting state‑of‑the‑art drug discovery methods.

About Receptor.AI

Receptor.AI, a U.S.-based TechBio company, is reshaping preclinical drug discovery through its advanced generative AI platforms. With a strong technology stack, proven results, and collaborations with Japanese pharmaceutical leaders such as Ono Pharmaceutical, it exemplifies the growing shift toward computational and data-driven R&D in biotech.

At the heart of Receptor.AI’s success is its multiplatform AI ecosystem, designed to accelerate the identification and optimization of novel therapeutics. This modular, end-to-end infrastructure addresses some of the most pressing challenges in drug discovery:

Built on extensive experience and over 40 successful joint discovery projects, Receptor.AI’s multiplatform ecosystem empowers researchers to design small molecules, peptides, and induced proximity agents with unprecedented speed and accuracy. By focusing on validated, modular workflows that integrate seamlessly into existing R&D processes, Receptor.AI has become a trusted partner to big pharma companies and academic institutions worldwide.

https://www.receptor.ai/

About PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics^® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics^® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and structure-based design, PepMetics^® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics.

https://prismbiolab.com/

Korea No.1 medical aesthetic brand launches online and in 380 Sephora offline stores

LOS ANGELES, March 13, 2026 /PRNewswire/ — REJURAN COSMETICS, No.1 medical aesthetic brand developed by global pharmaceutical biotechnology company PharmaResearch, recently announced its official launch at Sephora, marking a major milestone in the brand’s North American expansion. The brand is now available on sephora.com and will roll out across approximately 380 Sephora stores nationwide beginning March 16.

Powered by its patented c-PDRN® ingredient and proprietary DNA Optimizing Technology (DOT®), REJURAN® COSMETICS harnesses sustainably sourced wild salmon DNA to support skin renewal. Clinically designed to improve the look of texture, hydration, and radiance, the brand’s formulas help strengthen the foundations of healthy skin for a smoother, firmer-looking complexion. Trusted by dermatology clinics, skincare professionals, and celebrities worldwide, REJURAN® COSMETICS combines cutting-edge science with high-performance skincare.

The Sephora launch follows REJURAN COSMETICS’ early online debut on sephora.com on March 1, with in-store availability expanding across the United States starting March 16.

Key products available through Sephora include:

• REJURAN Turnover Ampoule
• REJURAN Dual Effect Ampoule
• REJURAN Rebalancing Toner
• REJURAN Nutritive Cream
• REJURAN Turnover Mask

REJURAN will also introduce a Sephora exclusive mini set.

To celebrate REJURAN’s launch at Sephora, REJURAN COSMETICS will host a series of interactive pop-up experiences across Los Angeles and Orange County—March 27 at The Americana at Brand, and March 28–29 at Irvine Spectrum Center. The events are designed to introduce consumers to REJURAN’s expertise in PDRN science while creating an engaging environment that brings the brand’s clinical innovation to life.

Prior to its Sephora debut, REJURAN COSMETICS entered the North American market primarily through online channels including Amazon and TikTok Shop. The Sephora partnership significantly expands the brand’s distribution footprint, bringing their products to hundreds of physical retail locations across the United States and strengthening direct engagement with consumers.

“Launching with Sephora represents an important milestone for REJURAN COSMETICS as we continue expanding in the North American market,” said a representative from PharmaResearch. “Through this partnership, we aim to further strengthen our brand presence and build deeper connections with consumers in the U.S. while continuing our global growth.”

Following the U.S. launch, the company plans to expand its distribution network across additional global markets, including Canada and Southeast Asia, as it continues establishing REJURAN Cosmetics as a leading global derma-cosmetic brand.

About REJURAN COSMETICS

REJURAN® COSMETICS is a premium derma-skincare brand developed by PharmaResearch, a global leader in regenerative science. Inspired by clinical expertise, the brand brings advanced skincare innovation into everyday routines. As Korea’s original PDRN-based skincare brand, REJURAN® Cosmetics is powered by patented c-PDRN® derived from sustainably sourced salmon DNA and PharmaResearch’s proprietary DNA Optimizing Technology (DOT®). The formulations are designed to help improve skin texture, hydration and radiance while supporting healthier, more resilient-looking skin.

Learn more at rejuranusa.com

SEOUL, South Korea, March 13, 2026 /PRNewswire/ — WIRobotics today announced it has been selected for the second cohort of the Physical AI Fellowship, a virtual program powered by Amazon Web Services (AWS) Startups and NVIDIA Inception that helps high-potential robotics startups build, refine, and scale physical AI solutions.

Following the success of the inaugural Fall 2025 cohort, the 2026 cohort brings together nine promising physical AI startups across agriculture, construction and renewable energy, industrial automation, retail and logistics, robotics data infrastructure, teleoperation, and humanoid robotics applications.

The Physical AI Fellowship provides hands-on technical guidance, compute resources, and go-to-market opportunities to help teams mature promising prototypes into reliable, real-world deployments. Fellows receive support from scientists and experts at the AWS Generative AI Innovation Center, AWS credits, and NVIDIA resources, along with access to MassRobotics’ facilities and its broader network in the robotics community.

This opportunity will support WIRobotics’ work to develop advanced humanoid robots that combine high-dexterity manipulation with AI-driven physical interaction for real-world environments. With AWS credits and expert guidance, NVIDIA’s physical AI stack , and MassRobotics’ testbed and network, WIRobotics will refine and deploy its humanoid robotics systems for real-world industrial, logistics, and service applications while validating performance in practical settings.

“We are honored that WIRobotics has been selected for the Physical AI Fellowship as the only humanoid robotics company in the cohort,” said Yong-Jae Kim, Co-CEO of WIRobotics. “By combining humanoid robotics technologies capable of human-like physical interaction with our AI expertise, we believe this will be a meaningful opportunity to explore new possibilities in Physical AI.”

Each Fellow will receive $200,000 in AWS credits, embedded support from the AWS Generative AI Innovation Center (GenAIIC) scientists and engineers and access to AWS’ cloud computing and AI technologies, access to NVIDIA’s physical AI stack including the NVIDIA Isaac frameworks and NVIDIA Cosmos world foundation models (plus free self-paced courses, hardware/software discounts and discounted instructor-led workshops from NVIDIA Training) via the NVIDIA Inception program, and ecosystem support from MassRobotics.

The Fellowship culminates in high-visibility showcases at AWS, NVIDIA, and MassRobotics events, including AWS re:Invent 2026.

For more information on the Physical AI Fellowship, visit https://www.massrobotics.org

About WIRobotics

WIRobotics (We Innovate Robotics) is a robotics company developing advanced wearable and humanoid robots designed to enhance human mobility and physical capabilities. The company’s first commercial product, a personal walking-assist robot powered by a single motor, has achieved commercial success in Korea and received four CES Innovation Awards over the past three years.

Building on its expertise in robotics hardware, control systems, and AI-driven interaction, WIRobotics is developing ALLEX, a general-purpose humanoid robot platform designed for real-world applications. Through its integrated hand–arm systems and high-dexterity manipulation capabilities, ALLEX is designed to enable the next generation of Physical AI.

For more information:

YouTube:  https://www.youtube.com/@WIRobotics
LinkedIn:  https://www.linkedin.com/company/103004622
TikTok:  https://www.tiktok.com/@wirobotics

BARCELONA, Spain, March 13, 2026 /PRNewswire/ — Alimentaria+Hostelco will return to Fira de Barcelona’s Gran Via venue from 23 to 26 March 2026, consolidating its position as a leading platform for the food, hospitality and foodservice value chain. In an edition marking Alimentaria’s 50th anniversary, the event will span 100,000 m² in seven pavilions, with international participation up 41% compared to 2024.

The show will bring together more than 3,300 companies, nearly 1,000 of them from 70 countries, representing more than 30% of the total. Europe, with Poland as the Country of Honour, together with Asia and Latin America, will make up the strongest international presence, underlining the event’s role as a strategic meeting point for the global industry. Confirmed international companies include KeHE, Bidfood, Bergfood, Cotswold Fayre, Sonae, PriceSmart, Walmart, GPA, La Comer, BigBasket and Alkosto.

Alimentaria+Hostelco 2026 reinforces its leadership in a historic edition

To support access to new markets and increase commercial opportunities, the organisers have invited 1,500 major buyers and importers from 100 countries, as well as 1,200 national buyers, with more than 14,500 business meetings expected.

Alimentaria+Hostelco 2026 will be organised into a number of specialised sectors. Intercarn will once again be the largest, with 350 companies across 15,000 m². Other featured areas will include Organic Foods, Alimentaria Trends and Fine Foods, focused on innovation; Grocery Foods, with the broadest cross-sector offer of the fair; Coffee, Bakery & Pastry, which doubles its space; as well as Interlact, Lands of Spain, Snacks, Biscuits & Confectionery, Expoconser, Restaurama, and International Pavilions.

Innovation will remain a central focus. The Alimentaria Hub will host 200 experts in sustainability, digitalisation, food safety and emerging trends. Innoval will showcase more than 300 product innovations, alongside 60 ventures in the Food & Hospitality Startups area.

The Horeca sector will occupy more than 20,000 m², bringing together 600 companies and 200 activities. The Horeca Hub will include Imagine Foodservice Europe and the new space, The Shift. The Bakery & Pastry Hub and The Coffee Stage will bring together leading figures in the sector. The programme will include competitions such as the First International Alimentaria Cooking Championship, sponsored by #alimentosdeespaña, the Horeca Awards, and several professional championships.

Alimentaria+Hostelco, organised by Alimentaria Exhibitions, a Fira de Barcelona company, expects to welcome more than 110,000 professional visitors, 25% of them international, reaffirming its leadership as the main platform for business, internationalisation and networking.

Keypoint Intelligence to share research and insights on major trends affecting the print industry

FAIRFIELD, N.J., March 13, 2026 /PRNewswire/ — Keypoint Intelligence will serve as the Thought Leadership Partner at FESPA Global Print Expo 2026. The event will take place May 19–22, 2026, at Fira Barcelona in Barcelona, Spain, bringing together print service providers, manufacturers, and industry leaders from around the world to explore the latest technologies and market developments in wide format, textile, and production print.

Building on the collaboration launched in 2025, Keypoint Intelligence will continue contributing research and market insights to the event program, helping attendees better understand developments across wide format, textile, and production print.

As Europe’s leading exhibition for wide format, textile, and specialty print, the Global Print Expo showcases innovations in digital printing, signage and graphics, apparel decoration, personalization, and production technologies. Through its continued partnership, Keypoint Intelligence will highlight major trends affecting the print industry, including artificial intelligence and automation, digital transformation, sustainability initiatives, workforce challenges, and advancements in production software and workflow optimization.

“Keypoint Intelligence provides the global print industry with independent research and insights that help organizations navigate change and drive strategic growth,” said Anthony Sci, President and CEO of Keypoint Intelligence. “Continuing our partnership with FESPA allows us to share critical intelligence on the technologies and market trends shaping the future of wide format printing, textile printing, and production workflows.”

Attendees of FESPA Global Print Expo 2026 can engage with Keypoint Intelligence and gain insight into new technologies and market developments affecting the print industry.

To learn more about FESPA Global Print Expo 2026, visit: https://europe.fespa.com/global-print-expo

About Keypoint Intelligence
For over 60 years, clients in the digital imaging industry have relied on Keypoint Intelligence for independent hands-on testing, lab data, and extensive market research to drive their product and sales success. Keypoint Intelligence has been recognized as the industry’s most trusted resource for unbiased information, analysis, and awards due to decades of analyst experience.

About FESPA
Founded in 1962, FESPA is a global federation of Associations for the screen printing, digital printing and textile printing community. FESPA’s dual aim is to promote screen printing and digital imaging and to share knowledge about screen and digital printing with its members across the world, helping them to grow their businesses and learn about the latest developments in their fast-growing industries.

HONG KONG, March 13, 2026 /PRNewswire/ — LiberNovo proudly announces that the LiberNovo Omni has been awarded the iF DESIGN AWARD 2026 in the Product Design – Beauty/Wellness category. The chair represents LiberNovo’s breakthrough approach to Dynamic Ergonomics. The iF DESIGN AWARD is widely regarded as one of the most respected awards in international design and recognizes innovative, functional, and user-centric designs.

Revolutionizing Ergonomics

The LiberNovo Omni was designed to revolutionize how people sit during long work hours. Unlike other office chairs that force people into unnatural positions and postures, the LiberNovo Omni introduces a new category of seating, the Dynamic Ergonomic Chair.

The chair supports your body as you naturally move throughout the day, so you can always adjust your position freely and still receive continuous support.

The LiberNovo Omni solves one of the biggest problems facing today’s work environment. As work has become more and more desk-based, people are spending more time than ever before sitting. Traditional office chairs are designed for stationary use and often don’t accommodate body movement, leading to lower back discomfort and strain.

Technologies Behind the Award-Winning Design

At the core of the LiberNovo Omni’s design is Dynamic Support, LiberNovo’s adaptive support system that automatically adjusts to posture changes in real time. Instead of requiring users to manually readjust their chairs throughout the day, Dynamic Support continuously responds to body movement, helping maintain balance and ergonomic alignment without interruption.

The chair also features LiberNovo’s Bionic FlexFit Backrest, an advanced ergonomic structure that contours to the natural curvature of the spine. Using multiple pivot points and adaptive panels, the backrest distributes pressure evenly across the back while allowing natural motion. This approach provides consistent support from the hips through the shoulders, creating a seating experience that adapts to the individual rather than forcing the individual to adapt to the chair.

The LiberNovo Omni also incorporates multiple recline modes, allowing users to shift naturally between focused work and more relaxed postures while maintaining continuous ergonomic support. For deeper recovery, the chair includes OmniStretch, a guided decompression feature that gently stretches the lower spine and helps relieve pressure accumulated during prolonged sitting.

Together, these technologies define a new approach to ergonomic seating built around movement, adaptability, and long-term physical support.

Design Philosophy

The development of the LiberNovo Omni focused on solving a longstanding challenge in chair design: balancing softness, structural support, and freedom of movement. Traditionally, improving one of these qualities has meant compromising another. The LiberNovo Omni was engineered to bring these elements together in a single system, combining comfort, stability, and natural mobility.

This approach reflects LiberNovo’s broader philosophy: the tools we use every day should work with the human body rather than against it. In modern work environments, productivity should not come at the expense of long-term health.

Design Collaboration

The chair was developed by the LiberNovo design team in Shenzhen, China, in collaboration with Kairos Innovation, an industrial design firm based there. Together, the teams focused on creating an ergonomic system that maintains support across the wide range of positions people naturally adopt while working throughout the day.

About the iF DESIGN AWARD

Established in 1954, the iF DESIGN AWARD is an internationally recognized standard for measuring design quality. Entries are selected using strict evaluation criteria, including innovation, functionality, ergonomics, and overall design impact.

In 2026, over 10,000 entries from more than 60 countries were submitted for consideration for the iF DESIGN AWARD. All entries were evaluated by an independent group of international design professionals, making the iF DESIGN AWARD one of the most highly respected design awards available today.

Looking Ahead

Receiving the iF DESIGN AWARD is a significant milestone for LiberNovo, demonstrating the company’s continued commitment to advancing ergonomic seating design.

The iF DESIGN AWARD highlights the increasing importance of designing workplace solutions that enable workers to be productive and support their long-term physical health and wellness.

As workspaces continue to evolve, LiberNovo believes seating should move away from static support systems toward more dynamic, human-centered designs.

The LiberNovo Omni embodies this vision by shifting ergonomic design away from static seating, creating a chair that adapts to the user rather than requiring the user to adapt to the chair.

About LiberNovo

LiberNovo is a design and technology company focused on advancing ergonomic innovation for modern work environments. Through a combination of advanced engineering and human-centered design, the company develops intelligent products that respond to the evolving ways people work and interact with their surroundings.